Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 2 |
2024 | 1 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
hayden f bell[Author]
(2 results)?
Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway.
Biochem J. 2022 Oct 14;479(19):2063-2086. doi: 10.1042/BCJ20220102.
Biochem J. 2022.
PMID: 36240066
Free PMC article.
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Bell HL, Blair HJ, Singh M, Moorman AV, Heidenreich O, van Delft FW, Lunec J, Irving JAE.
Bell HL, et al.
Cancer Cell Int. 2023 Sep 15;23(1):202. doi: 10.1186/s12935-023-03057-8.
Cancer Cell Int. 2023.
PMID: 37715172
Free PMC article.
Item in Clipboard
Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.
Stölzel F, Fordham SE, Nandana D, Lin WY, Blair H, Elstob C, Bell HL, Mohr B, Ruhnke L, Kunadt D, Dill C, Allsop D, Piddock R, Soura EN, Park C, Fadly M, Rahman T, Alharbi A, Wobus M, Altmann H, Röllig C, Wagenführ L, Jones GL, Menne T, Jackson GH, Marr HJ, Fitzgibbon J, Onel K, Meggendorfer M, Robinson A, Bziuk Z, Bowes E, Heidenreich O, Haferlach T, Villar S, Ariceta B, Diaz RA, Altschuler SJ, Wu LF, Prosper F, Montesinos P, Martinez-Lopez J, Bornhäuser M, Allan JM.
Stölzel F, et al. Among authors: bell hl.
JCI Insight. 2023 Jan 24;8(2):e150368. doi: 10.1172/jci.insight.150368.
JCI Insight. 2023.
PMID: 36480300
Free PMC article.
Item in Clipboard
Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Bell HL, Blair HJ, Jepson Gosling SJ, Galler M, Astley D, Moorman AV, Heidenreich O, Veal GJ, van Delft FW, Lunec J, Irving JAE.
Bell HL, et al.
Leukemia. 2024 Jun;38(6):1223-1235. doi: 10.1038/s41375-024-02241-7. Epub 2024 Apr 10.
Leukemia. 2024.
PMID: 38600316
Free PMC article.
Item in Clipboard
Cite
Cite